Robert LeBoyer
Stock Analyst at Noble Capital Markets
(2.24)
# 2,673
Out of 4,931 analysts
18
Total ratings
43.75%
Success rate
10.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding | Reiterates: Outperform | $70 | $46.92 | +49.19% | 2 | Mar 20, 2025 | |
| NTRB Nutriband | Initiates: Outperform | $13 | $7.06 | +84.14% | 1 | Jan 22, 2025 | |
| GOVX GeoVax Labs | Maintains: Outperform | $6 → $10 | $0.67 | +1,393.88% | 2 | Aug 19, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Outperform | $60 | $4.06 | +1,377.83% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $60 | $10.58 | +467.11% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $2.75 | +264.30% | 1 | Sep 27, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $1.48 | +845.95% | 1 | Feb 21, 2023 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $0.95 | +741.40% | 2 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | $120 | $0.76 | +15,714.44% | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $11.60 | - | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $11.22 | +7.00% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9,900,000 | $6.99 | +141,630,801.29% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.10 | - | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $4.02 | +273.13% | 2 | Mar 8, 2018 |
Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $46.92
Upside: +49.19%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $7.06
Upside: +84.14%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $6 → $10
Current: $0.67
Upside: +1,393.88%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $4.06
Upside: +1,377.83%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $10.58
Upside: +467.11%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $2.75
Upside: +264.30%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.48
Upside: +845.95%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $0.95
Upside: +741.40%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $0.76
Upside: +15,714.44%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $11.60
Upside: -
Sep 28, 2020
Initiates: Buy
Price Target: $12
Current: $11.22
Upside: +7.00%
Aug 24, 2020
Initiates: Buy
Price Target: $9,900,000
Current: $6.99
Upside: +141,630,801.29%
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $14.10
Upside: -
Mar 8, 2018
Initiates: Buy
Price Target: $15
Current: $4.02
Upside: +273.13%